Brief: Eiger BioPharmaceuticals And AnGes Enter Partnership For Lonafarnib In Japan
10/05/2022 22:30
May 10 (Reuters) - AnGes Inc 4563.T :
* EIGER BIOPHARMACEUTICALS AND ANGES ANNOUNCE EXCLUSIVE
PARTNERSHIP FOR REGULATORY APPROVAL AND COMMERCIALIZATION OF
ZOKINVY® (LONAFARNIB) IN JAPAN
* EIGER BIOPHARMACEUTICALS INC - ANGES IS RESPONSIBLE FOR
OBTAINING AND MAINTAINING REGULATORY APPROVAL FOR ZOKINVY IN
JAPAN
* EIGER BIOPHARMACEUTICALS INC - EIGER WILL RECEIVE UPFRONT
AND
MILESTONE PAYMENTS UP TO $1.5M AS WELL AS EARN REVENUE FROM SALE
OF ZOKINVY TO ANGES
Source text for Eikon: ID:nPn8jNQcqa
Further company coverage: 4563.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001